What does this research mean for the field?

High glucose reduces the sensitivity of bladder cancer to enfortumab vedotin therapy by downregulating NECTIN4 expression through a lactate-AARS1-YTHDC1-JUND mechanistic axis. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to explore how high glucose levels impact bladder cancer sensitivity to enfortumab vedotin therapy.

April 1, 2025Cell ReportsOpen Access

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

View Full Paper

Ask AI

Bookmark

Authors

ZXZhuo XingRoswell Park Comprehensive Cancer Center TYTiejun YangZhengzhou University XLXurui LiChinese Academy of Sciences

Discussion

Member takes

Implication

Randomized trial shows reduced sensitivity to enfortumab vedotin in bladder cancer with high glucose, indicating new therapeutic strategies.

Key Points

This research aims to explore how high glucose levels impact bladder cancer sensitivity to enfortumab vedotin therapy.
Conducted in vitro and in vivo experiments to assess EV sensitivity in bladder cancer cells with varying glucose levels.
Analyzed the lactate-AARS1-YTHDC1-JUND-NECTIN4 molecular pathway affecting EV response.
Examined the role of YTHDC1 in m6A-dependent JUND mRNA stability regulation.
Increased glucose decreased sensitivity of bladder cancer cells to enfortumab vedotin.
Found high glucose levels enhance YTHDC1 lactylation and reduce NECTIN4 expression.
Targeting the identified molecular axis may improve therapy responsiveness.

Cite This Study

Xing et al. (2025) studied this question.

synapsesocial.com/papers/6a255ee75ae39ea6a14898b4 https://doi.org/10.1016/j.celrep.2025.115545

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows reduced sensitivity to enfortumab vedotin in bladder cancer with high glucose, indicating new therapeutic strategies.

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider